Global Investors Eye Bangkok's Rarest Luxury Wellness Penthouses at Award-Winning ROMM Convent
Multi-Award Winning Development Captures International Attention with 2-Star Fitwel Certification, Asia Pacific Property Awards, and PropertyGuru Excellence Recognition
BANGKOK, THAILAND - Media OutReach Newswire - 4 June 2025 - Proud Real Estate has unveiled an extraordinary investment opportunity at ROMM Convent —Bangkok's premier wellness-integrated residence in the prestigious Sathorn-Silom CBD. The only two duplex sky penthouses available, representing the pinnacle of luxury wellness living in Southeast Asia, are now available to discerning global investors.
ROMM CONVENT - Duplex Sky Penthouse
These architectural masterpieces have captured international attention, with ROMM Convent receiving multiple prestigious accolades including Best Condo Development and Best Architectural Design at the Asia Pacific Property Awards, Best Wellness Residences Development from PropertyGuru, and a coveted 2-Star Fitwel Built Certification—a global standard in wellness design excellence.
Investors are drawn by proven returns, with rental yields of 4–5.8% per annum and capital gains averaging 3–5.4% annually. Amid a climate of accelerating international demand, ROMM Convent stands out as both a secure asset and an aspirational lifestyle investment—offering exceptional value in one of Southeast Asia's fastest-growing real estate markets.
Bangkok's Luxury Market: A Magnet for Global Capital
Bangkok continues to command the interest of investors worldwide, with the luxury condominium segment outpacing regional peers and anticipated to achieve sustained annual growth of 3–5% through 2027. In 2024 alone, international buyers accounted for 39% of total sales value, with large-format residences over 150 sq.m. in prime central locations witnessing robust absorption.
The Silom–Sathorn district is in the midst of a transformation, with over THB 600 billion in public and private investment projected through 2035. This surge of mega-projects is redefining the urban landscape, creating new opportunities for capital appreciation and rental demand—particularly as Bangkok's tourism sector continues its strong recovery.
ROMM Convent : A Sanctuary for Global Citizens
Strategically positioned for expatriates, professionals, digital nomads, and retirees, ROMM Convent offers unrivaled access to both tradition and modernity. Residents enjoy proximity to Bangkok's leading international schools—including St. Andrews Sathorn, Shrewsbury International, and King's College—as well as world-class medical centers such as BNH Hospital, MedPark, and King Chulalongkorn Memorial Hospital. With average rental rates of THB 800–1,200 per sq.m. per month, the area delivers healthy yields of 4–5.8% per year and robust capital gains of approximately 3–5.4% annually, underpinned by consistently high tenant demand.
The Pinnacle of Wellness-Integrated Living
The Duplex Sky Penthouses at ROMM Convent are a masterclass in architectural innovation and holistic well-being. Each residence spans 418.61–467.86 sq.m., offering house-like layouts with soaring 6.45-meter ceilings and panoramic skyline views, including Bangkok's most iconic landmarks. Private rooftop gardens create a tranquil green haven, seamlessly visible from both living and bedroom spaces.
Exceptional Features Include: • Ultra-Exclusive Ownership: Only two duplex penthouses available. • House-Like Living: Two-story layout located in the heart of Bangkok's CBD • Skyline Views: Panoramic vistas in three directions, including iconic landmarks like MahaNakhon and One Bangkok • Private Rooftop Garden: A serene green escape visible from the main living and bedrooms • Signature Design Elements: Full-height glass, custom wellness detailing, and a serene rooftop retreat. • Gourmet Entertaining: Ice Jade kitchen island, Gorenje ORA ITO appliances, and a 46-bottle wine cellar. • Sophisticated Finishes: Engineered walnut floors, stone-clad kitchens, premium fixtures, and bespoke cabinetry. • Grand Proportions: Four bedrooms, five bathrooms, powder room, and a flexible multi-purpose space.
Wellness Technology & Privileged Services: • 2-Star Fitwel Certified Wellness: Recognized global standards in health-optimized living. • 24/7 Health Butler Concierge: Personalized healthcare coordination and support. • Six Levels of Wellness Amenities: Thoughtfully curated for holistic mind-body well-being. • Smart Home Ecosystem: Advanced technology for air quality, energy efficiency, and comfort. • Exclusive Healthcare Partnerships: VVIP privileges with BNH Hospital and BeDee by BDMS.
Unmatched Value in Bangkok's Central Business District
Starting at just THB 290,000 per sq.m., ROMM Convent's Duplex Sky Penthouses represent one of the most compelling luxury investments in the Sathorn district—delivering exceptional value compared to global property capitals. Ownership is further enhanced by immediate access to VVIP medical privileges at BNH Hospital including special discounts and personalized care from Thailand's top-tier medical professionals—, ensuring both peace of mind and premier healthcare for residents and their families.
Limited International Allocation: Secure Your Early Investor Advantage
As foreign ownership quotas rapidly reach capacity, Proud Real Estate is pleased to offer the exclusive Early Investor Package (available until June 30, 2025). This limited-time opportunity includes bespoke layout customization and privileged access to tailored services—making now the optimal moment for international investors to secure their stake in one of Bangkok's most rarefied addresses.
Invest in an Iconic Lifestyle at ROMM Convent – Where Wellness Meets Luxury
Seize the opportunity to own one of the last two Duplex Sky Penthouses at ROMM Convent, where visionary design, holistic wellness, and world-class investment potential converge. Availability is strictly limited—act now to elevate your lifestyle and portfolio with Bangkok's most coveted luxury residence.
For more information and personalized assistance, please visit Proud Real Estate or call +662-026-8999.
Note: This press release contains forward-looking statements about market performance and investment returns. Actual results may vary. Investors should conduct their own due diligence before making investment decisions.
Hashtag: #ProudRealestate #AllisWell #RommConvent #LuxuryWellnessResidences #CondoSathorn #CondoHighRise #Condo #Bangkok #CBD
https://www.proudrealestate.co.th/
https://www.facebook.com/proudrealestateplc
https://www.instagram.com/proud_realestate/
The issuer is solely responsible for the content of this announcement.
PROUD REAL ESTATE PUBLIC COMPANY LIMITED
Proud Real Estate is Thailand's leading luxury wellness-focused property developer, renowned for creating holistic living environments that seamlessly integrate health optimization, sustainability, and timeless design. With a portfolio of internationally awarded projects, Proud Real Estate consistently delivers above-market investment returns while setting new benchmarks in luxury and resident well-being. The company gained global recognition for the development of InterContinental Residences Hua Hin, one of only eight world-class branded residences under the InterContinental name—further solidifying Proud's reputation for excellence in luxury real estate.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
H.C. Wainwright Reiterates Buy Rating on Immix Biopharma (IMMX) Following Promising Interim Results from NXC-201 Trial
On June 4, analyst Robert Burns of H.C. Wainwright reiterated a Buy rating on Immix Biopharma, Inc. (NASDAQ:IMMX) with a price target of $7.00. The analyst based the rating on the promising interim results from the NEXICART-2 Phase 1/2 clinical trial of NXC-201, presented at the 2025 American Society of Clinical Oncology Annual Meeting (ASCO 2025) in Chicago, Illinois. The trial assessed the efficacy of NXC-201 in patients with relapsed/refractory AL amyloidosis and delivered a 100% response rate, with a considerable portion attaining a complete hematologic response. The analyst reasoned that the absence of hematologic relapse or progression and the rapid mean time to response further highlight NXC-201's potential as a viable treatment. A doctor in a white coat discussing clinical trial results with a patient in an oncology practice. Burns also reasoned that NXC-201 appears to have a favorable safety profile, as no patients experienced severe cytokine release syndrome or neurotoxicity. While he highlighted the need for longer-term follow-up and the small sample size, the analyst stated that the interim results are promising when compared to existing treatments. This condition does not have FDA-approved agents, and there exists a fragmented treatment landscape post-frontline therapy, factors that suggest the notable market opportunity for NXC-201 and support the buy rating for Immix Biopharma, Inc. (NASDAQ:IMMX). Immix Biopharma, Inc. (NASDAQ:IMMX) is a biopharmaceutical company that develops therapies for inflammatory diseases and cancer. While we acknowledge the potential of IMMX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Sign in to access your portfolio
Yahoo
4 hours ago
- Yahoo
Shams Charania Drops Major Kevin Durant Trade Update on Wednesday
Shams Charania Drops Major Kevin Durant Trade Update on Wednesday originally appeared on Athlon Sports. According to Shams Charania of ESPN, the Phoenix Suns are hiring Cleveland Cavaliers assistant Jordan Ott as their new head coach. Advertisement The Suns fired Mike Budenholzer after one season. Budenholzer replaced Frank Vogel, who was also fired after one season. Phoenix missed the playoffs and play-in tournament this year despite having Kevin Durant, Devin Booker and Bradley Beal. Charania is reporting that Booker was involved in the Suns' coaching search process during the final stages and stamped Ott as his top choice. Durant, though, wasn't involved. That's because the Suns are expected to work together with the superstar and his business partner, Boardroom CEO Rich Kleiman, on a trade. "The Suns will work with All-Star forward Kevin Durant and his business partner, Boardroom CEO Rich Kleiman, on his next landing spot," Charania wrote. "He is expected to have a robust market of approximately four to six seriously interested teams this offseason, sources said." Phoenix Suns star Kevin Chenoy-Imagn Images A future Hall of Famer, Durant has one year remaining on his contract. The small forward will make $54.7 million next season. Advertisement Durant turns 37 in September. He averaged 26.6 points, 6.0 rebounds and 4.2 assists for the Suns this season while shooting 52.7% from the field, 43.0% from beyond the arc and 83.9% from the free-throw line. Durant has career averages of 27.2 points, 7.0 rebounds and 4.4 assists with the Oklahoma City Thunder, Golden State Warriors, Brooklyn Nets and Suns. KD won two championships and two Finals MVPs with the Warriors but hasn't gotten back to the NBA Finals since leaving Golden State for Brooklyn in 2019. The Suns acquired Durant from the Nets in 2023. They have won only one postseason series since then. Related: Suns Could Trade Kevin Durant to Texas Team 'Right Before' 2025 NBA Draft This story was originally reported by Athlon Sports on Jun 4, 2025, where it first appeared.
Yahoo
4 hours ago
- Yahoo
New coronavirus discovered in China ‘only small step' from infecting humans
A new coronavirus discovered in China is only a small step from mutating and causing another global pandemic, experts have warned. Scientists believe the variant, called HKU5-CoV-2, may infect a broader range of animals than Covid-19 – which caused millions of deaths – and may have more potential for jumping between species. US researchers fear that HKU5-CoV-2, found in China, in February, could also infect humans, leading to a widespread outbreak. The new study, published in Nature Communications, looked at a lesser-known group of coronaviruses called merbecoviruses, which includes HKU5 and MERS-CoV, which is responsible for the deadly Middle East Respiratory Syndrome. The team from Washington State University looked at how the new pathogen interacts with human cells. They found that a small change in the virus's spike protein could allow it to attach to human ACE2 cells in people's throats, mouths and noses. HKU5-CoV-2 can infect and replicate inside human cells in both the airways and gut. According to the World Health Organisation, about 35 per cent of people infected with Middle East Respiratory Syndrome die. Since 2012, some 27 countries have reported cases, leading to 858 known deaths due to the infection, which spread from camels. But when HKU5 was discovered in February, scientists warned against exaggerating the risks because it does not enter human cells as readily as Sars-CoV-2, which caused Covid-19. HKU5 was first detected in bats by scientists from the Chinese laboratory where some say Covid originated in 2019. Prof Michael Letko, a virologist who co-led the study, said: 'HKU5 viruses in particular really hadn't been looked at much, but our study shows how these viruses infect cells. 'What we also found is HKU5 viruses may be only a small step away from being able to spill over into humans.' When Covid-19 emerged it was widely blamed on markets in China where different breeds of wild animal are kept caged and often slaughtered close to other animals. Meat is sold at the open-air stalls. Critics said the markets were the perfect breeding ground for new zoonotic diseases – those that spread to humans – to emerge. The scientists, whose experiments studied how the new pathogen interacts with human cells, believe the virus would have to carry certain mutations if it were to infect humans. 'These viruses are closely related to MERS, so we have to be concerned if they ever infect humans,' Prof Letko said. 'While there's no evidence they've crossed into people yet, the potential is there and that makes them worth watching.'
